Givaudan eyes growth in Brazil
This article was originally published in The Rose Sheet
Executive Summary
Swiss flavor and fragrance firm unveiled its five-year plan in Zurich Aug 31, indicating that developing markets will play an increasing role in corporate growth. Givaudan expects Brazil to be largest-value market for fine fragrance by 2014, outpacing the U.S., based on Euromonitor data. Company recently opened a Creative Center in Brazil and plans to expand its creative resources elsewhere in Latin America. Developing markets currently account for 41% of Givaudan's overall sales and are expected to contribute 50% of sales by 2015. Revenue for the first half of 2010 rose 10.5% compared with the prior-year period, driven by sales of consumer products and increased flavors sales in Latin America, Givaudan says. Firm's overall objective is to grow organically between 4.5% and 5.5% annually, based on assumed market growth of 2% to 3%, and to continue our path of market share gain over the next five years," CEO Gilles Andrier states in a company release
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.